8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。

智通财经08-04

8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。从沃森生物获悉双价人乳头瘤病毒疫苗为全球第四家获得WHO预认证的HPV疫苗（包括双价、四价、九价）企业此前有默沙东的四价和九价、葛兰素史克和万泰生物的二价。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2456270107?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-04 07:19","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2456270107","market":"hk","top_or_hot":-1,"title":"8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。","media":"智通财经","content":"<div>\n<p>8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。从沃森生物获悉双价人乳头瘤病毒疫苗为全球第四家获得WHO预认证的HPV疫苗（包括双价、四价、九价）企业此前有默沙东的四价和九价、葛兰素史克和万泰生物的二价。...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-04 07:19 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。从沃森生物获悉双价人乳头瘤病毒疫苗为全球第四家获得WHO预认证的HPV疫苗（包括双价、四价、九价）企业此前有默沙东的四价和九价、葛兰素史克和万泰生物的二价。...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2456270107","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2456270107","pubTimestamp":1722727189,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","300142":"沃森生物","603392":"万泰生物","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0971552830.HKD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AM\" (HKDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1645745479.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (HKDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","GSK":"葛兰素史克","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK1200":"软饮料","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK0046":"生物疫苗","BK5011":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1302929846.USD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AMG\" (USDHDG) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","GSK.UK":"葛兰素史克","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","MRK":"默沙东","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4588":"碎股","09633":"农夫山泉","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"On August 3, Watson Bio announced the bivalent human papilloma virus independently developed by Yuxi Zerun Biotechnology Co., Ltd., a subsidiary of Watson Bio","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"300142":1,"603392":1,"MRK":1,"GSK.UK":1,"GSK":1,"09633":1},"content_text":"8月3日沃森生物宣布沃森生物旗下的玉溪泽润生物技术有限公司自主研发的双价人乳头瘤病毒疫苗（沃泽惠）于8月2日通过了世界卫生组织（WHO）预认证标志该疫苗的安全性、有效性、质量可控性符合WHO标准生产企业生产管理体系达到WHO GMP要求。从沃森生物获悉双价人乳头瘤病毒疫苗为全球第四家获得WHO预认证的HPV疫苗（包括双价、四价、九价）企业此前有默沙东的四价和九价、葛兰素史克和万泰生物的二价。沃森生物表示此次获得WHO PQ认证的双价HPV疫苗目前设计年产能2000万剂。沃森生物董事长李云春在2020年全球疫苗峰会上也承诺“拿出一半以上的产能供应全球市场。”","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2456270107"}